Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19

Author:

Servian Carolina do Prado,Spadafora-Ferreira Mônica,Anjos Déborah Carolina Carvalho dos,Guilarde Adriana Oliveira,Gomes-Junior Antonio Roberto,Borges Moara Alves Santa Bárbara,Masson Letícia Carrijo,Silva João Marcos Maia,de Lima Matheus Henrique Assis,Moraes Brenda Grazielli Nogueira,Souza Sueli Meira,Xavier Luiz Eterno,de Oliveira Denise Cristina André,Batalha-Carvalho João Victor,Moro Ana Maria,Bocca Anamélia Lorenzetti,Pfrimer Irmtraut Araci Hoffmann,Costa Nádia Lago,Feres Valéria Christina de Rezende,Fiaccadori Fabiola Souza,Souza Menira,Gardinassi Luiz Gustavo,Durigon Edison Luiz,Romão Pedro Roosevelt Torres,Jorge Soraia Attie Calil,Coelho Verônica,Botosso Viviane Fongaro,Fonseca Simone Gonçalves

Abstract

IntroductionInfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces rapid production of IgM, IgA, and IgG antibodies directed to multiple viral antigens that may have impact diverse clinical outcomes.MethodsWe evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).ResultsThis study included 193 coronavirus disease 2019 (COVID-19) participants classified as mild, moderate, severe, critical, and fatal and 27 uninfected controls. In T1, we identified differential antibody profiles associated with distinct clinical presentation. The mild group presented lower levels of anti-NP IgG, and IgA (vs moderate and severe), anti-NP IgM (vs severe, critical and fatal), anti-Spike IgA (vs severe and fatal), and anti-RBD IgG (vs severe). The moderate group presented higher levels of anti-RBD IgA, comparing with severe group. The severe group presented higher levels of anti-NP IgA (vs mild and fatal) and anti-RBD IgG (vs mild and moderate). The fatal group presented higher levels of anti-NP IgM and anti-Spike IgA (vs mild), but lower levels of anti-NP IgA (vs severe). The levels of nAb was lower just in mild group compared to severe, critical, and fatal groups, moreover, no difference was observed among the more severe groups. In addition, we studied 82 convalescent individuals, between 31 days to 6 months (T2) or more than 6 months (T3), PSO, those: 12 mild, 26 moderate, and 46 severe plus critical. The longitudinal analyzes, for the severe plus critical group showed lower levels of anti-NP IgG, IgA and IgM, anti-Spike IgA in relation T3. The follow-up in the fatal group, reveals that the levels of anti-spike IgG increased, while anti-NP IgM levels was decreased along the time in severe/critical and fatal as well as anti-NP IgG and IgA in several/critical groups.DiscussionIn summary, the anti-NP IgA and IgG lower levels and the higher levels of anti-RBD and anti-Spike IgA in fatal compared to survival group of individuals admitted to the intensive care unit (ICU). Collectively, our data discriminate death from survival, suggesting that anti-RBD IgA and anti-Spike IgA may play some deleterious effect, in contrast with the potentially protective effect of anti-NP IgA and IgG in the survival group.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference69 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet (London England),2020

2. RitchieH MathieuE Lucas Rodés-GuiraoCA GiattinoC Ortiz-OspinaE HasellJ Coronavirus Pandemic (COVID-19) - Our World in Data2020

3. SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development;Kaur;Int J Biol Macromol,2021

4. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020

5. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2;Yan;Science (80-),2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3